None
Quote | Marker Therapeutics Inc. (NASDAQ:MRKR)
Last: | $5.19 |
---|---|
Change Percent: | 0.0% |
Open: | $5.3 |
Close: | $5.19 |
High: | $5.3 |
Low: | $5.09 |
Volume: | 6,378 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Marker Therapeutics Inc. (NASDAQ:MRKR)
2024-06-28 11:52:51 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Marker Therapeutics (NASDAQ: MRKR ) just reported results for the fourth quarter of 2023. Marker Therapeutics reported earnings per share of -30 cents. The company rep...
2024-05-15 17:07:37 ET More on Marker Therapeutics Seeking Alpha’s Quant Rating on Marker Therapeutics Historical earnings data for Marker Therapeutics Financial information for Marker Therapeutics Read the full article on Seeking Alpha For fur...
Message Board Posts | Marker Therapeutics Inc. (NASDAQ:MRKR)
Subject | By | Source | When |
---|---|---|---|
https://finance.yahoo.com/news/marker-therapeutics-reports-mt-401-110000404.html | abracky | investorshub | 06/26/2023 4:10:50 PM |
https://www.globenewswire.com/en/news-release/2023/06/26/2694294/0/en/Marker-The | jobynimble | investorshub | 06/26/2023 1:19:31 PM |
My pleasure | jobynimble | investorshub | 06/26/2023 1:13:54 PM |
So my obvious question would be: with all | microcapbiotech | investorshub | 06/26/2023 1:10:23 PM |
non-clinical data on its lead multi-tumor-associated antigen (multiTAA)-specific | microcapbiotech | investorshub | 06/26/2023 1:04:16 PM |
News, Short Squeeze, Breakout and More Instantly...
Marker Therapeutics Inc. Company Name:
MRKR Stock Symbol:
NASDAQ Market:
Marker Therapeutics Inc. Website:
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study Study participant with Non-Hodgkin’s Lymphoma who relapsed within 90 days of anti-CD19 CAR T cell therapy remains in complete response...
Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was presented at the 11 th Global Summit on Hematologic Malignancies in Whistler, BC, Canada Study participants tolerated initial dose level well and demonstrated durab...